Английская Википедия:ABNCoV2

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Use dmy dates Шаблон:Infobox drug Шаблон:COVID-19 pandemic sidebar ABNCoV2 is a cVLP COVID-19 vaccine candidate developed by Expres2ion Biotechnologies and Adaptvac, outlicensed to Bavarian Nordic.[1][2][3][4]

On 9 August 2021, it was announced that the first round of trials of the vaccine had been finalized with good results among 45 test subjects.[5]

References

Шаблон:Reflist

Шаблон:Scholia

Шаблон:Vaccines Шаблон:COVID-19 pandemic Шаблон:Portal bar


Шаблон:COVID19-vaccine-stub Шаблон:Vaccine-stub